Idea or Concept
WuXi Biologics’ ADC Spinout Sees Revenue Surge Amid Biosecure Threat
WuXi Biologics, ADC spinout, revenue jump, Biosecure risk, CRDMO, bioconjugate market
Astellas Employee Indicted by China’s Prosecutors on Espionage Charges
Astellas Pharma, China, Japan, espionage, indictment, diplomatic tensions
Novo Nordisk’s Wegovy Sales Shortfall: A Rare Setback for the Danish Drugmaker
Novo Nordisk, Wegovy, weight-loss drug, sales shortfall, stock performance, pharmaceutical industry
Symbiotic Capital Launches with $600M, Ties to Arie Belldegrun’s Bellco
Symbiotic Capital, Arie Belldegrun, Bellco, $600M, credit firm, biotech, private equity
Nuvation Bio Halts Development of BET Inhibitor NUV-868 Following Interim Phase 1 Data Review
Nuvation Bio, BET inhibitor, NUV-868, Phase 1 data, oncology drug, safety and efficacy, clinical trials
23andMe Board Rejects CEO Anne Wojcicki’s Take-Private Plan, Requests Changes
23andMe, Anne Wojcicki, take-private plan, board rejection, financing, stock price, shareholders
Vertex Pharmaceuticals Abandons Two Phase I AATD Drug Candidates Due to Disappointing Data
Vertex Pharmaceuticals, AATD, alpha-1 antitrypsin deficiency, drug candidates, Phase I trials, disappointing data
Impact of New CDC Guidelines on RSV Vaccine Makers
RSV vaccine, CDC guidelines, vaccine makers, Moderna, Pfizer, GSK, Guillain-Barré syndrome, vaccination recommendations
Biopharma Layoff Tracker 2024: FibroGen, Pfizer, Cue, and More Cut Staff
Biopharma layoffs, FibroGen, Pfizer, Cue, Anokion, biotech industry, job cuts, restructuring initiatives
Cognition Therapeutics’ Stock Plummets After Alzheimer’s Drug Misses Cognitive Endpoint
Cognition Therapeutics, Alzheimer’s disease, cognitive endpoint, stock decline, clinical trial